Regulation of the expression of the human immunodeficiency virus (HIV) genome is accomplished in large part by controlling transcription elongation. The viral protein Tat hijacks the host cell's RNA polymerase II elongation control machinery through interaction with the positive transcription elongation factor, P-TEFb, and directs the factor to promote productive elongation of HIV mRNA. Here we describe the crystal structure of the TatNP-TEFb complex containing HIV-1 Tat, human Cdk9 (also known as CDK9), and human cyclin T1 (also known as CCNT1). Tat adopts a structure complementary to the surface of P-TEFb and makes extensive contacts, mainly with the cyclin T1 subunit of P-TEFb, but also with the T-loop of the Cdk9 subunit. The structure provides a plausible explanation for the tolerance of Tat to sequence variations at certain sites. Importantly, Tat induces significant conformational changes in P-TEFb. This finding lays a foundation for the design of compounds that would specifically inhibit the TatNP-TEFb complex and block HIV replication.
According to the most recent UNAIDS AIDS Epidemic Update, as of the end of 2008, over 33 million people were living with HIV. Although the number of people infected has increased about 30% over the last 10 years, part of the increase is due to improved antiretroviral therapies and an increase in the number of people treated. Unfortunately, strains of HIV that are resistant to current anti-HIV drugs arise rapidly due to the error-prone reverse transcription step in the viral life cycle, and to a very high frequency of recombination that leads to a generation of mutant viruses that are unresponsive to the drugs 1 . Because of this and the lack of effective vaccines 2 , the search for new and better anti-HIV therapies continues. Most current HIV drugs inhibit viral enzymes, but host proteins that interact with viral proteins are also potential targets. One such host protein is the positive transcription elongation factor, P-TEFb, which interacts with the viral transactivator of transcription, Tat [3] [4] [5] .
P-TEFb has a key role in regulating the elongation phase of transcription by RNA polymerase II 6 . It is a cyclin-dependent kinase comprised of Cdk9 paired with one of several cyclin subunits, and in its active form is responsible for relief of the block to promoter proximally paused polymerases [7] [8] [9] . P-TEFb is generally required for the generation of mRNAs 10 and is recruited to genes by a variety of gene-specific proteins including NFkB, CIITA and nuclear receptors, as well as more generally by the bromodomain containing protein BRD4 (refs 6, 11) . The activity of P-TEFb is globally regulated by reversible association with the 7SK snRNP (small nuclear ribonucleoprotein particle) in which it is held in an inhibited state by an RNA-binding protein HEXIM1 or HEXIM2 (refs 6, 11, 12) .
HIV has evolved to manipulate both the Cdk9Ncyclin T1 form of P-TEFb and the cellular process controlling P-TEFb. Expression of HIV Tat in otherwise uninfected cells leads to the release of P-TEFb from the 7SK snRNP and the formation of a TatNP-TEFb complex 13 . During an active HIV infection, the TatNP-TEFb complex is recruited to the transactivation response element, TAR, which is manifested in the first 59 nucleotides of the nascent HIV transcript 5, [14] [15] [16] . In addition to providing a means to recruit P-TEFb to promoter proximally stalled polymerases engaged in the HIV long terminal repeat (LTR), Tat stimulates the kinase activity and changes the substrate specificity of P-TEFb 17 .
Here we report the high-resolution crystal structures of the TatNP-TEFb complex and the TatNP-TEFb complex with bound ATP analogue adenylyl imidodiphosphate (AMP-PNP) and magnesium ion (further referred to as TatNP-TEFbNATP). The structures reveal that Tat interacts with both the cyclin T1 and Cdk9 subunits of P-TEFb, and provide evidence for a Tat-induced conformational change in P-TEFb. Our findings also provide a structural basis for the design of compounds that would specifically inhibit HIV transcription.
Crystal structure of TatNP-TEFb complex
The structure of the TatNP-TEFb complex is refined at 2.1 Å resolution to an R of 21.9% and R free of 26.4%, and the structure of the TatNP-TEFbNATP is refined at 3.0 Å resolution to an R of 21.8% and R free of 28.6%. The Cdk9 subunit is phosphorylated at Thr 186 and is in a conformation characteristic for active cyclin-dependent kinases 18 .
The overall structure of the TatNP-TEFbNATP complex depicted in Fig. 1 shows that Tat acquires an extended conformation mainly through interactions with cyclin T1 (see Supplementary Fig. 1 for the definition of secondary structure elements). As expected from earlier biochemical studies 19 , Tat forms a Zn-mediated bridge with Cys 261 of cyclin T1. Tat binding to P-TEFb buries 3,499 Å 2 of surface area, of which 88% is on cyclin T1 and 12% is on Cdk9. Clearly, Tat has evolved to bind tightly to P-TEFb as 37% of its folded portion (amino acids 1-49) surface is complementary to the kinase. The amount of surface buried between P-TEFb and Tat is double the average value for stable protein-protein interactions 20 . The CDKcyclin interaction surface is smaller in P-TEFb than in other such complexes 21 . However, Tat augments it by inserting in a groove at the heterodimer interface and leading to a more stable and more active P-TEFb complex 17 .
Tat is encoded by two exons. Amino acids 1-72 encoded by the first exon are highly conserved and comprise five regions ( Fig. 2a ) that are sufficient for transactivation of the viral LTR promoter. The first three regions constitute a minimal activation domain capable of binding to cyclin T1. Indeed, the residues 1-49 are ordered in the crystal structure of TatNP-TEFb, whereas the density for the rest of Tat (residues 50-86) is not defined.
The acidic/proline-rich region is in an extended loop conformation and folded as a random coil with two type II b turns and one type II9 b turn ( Fig. 2b, c) . The mutations of the acidic or proline residues as well as deletion mutants within this region impair the activity of Tat 22 . A cysteine-rich region and core regions form a more compact structure with a random coil, two helices, a tail, and two bound Zn ions ( Fig. 2b, c) . The short 3 10 -helix is located between the Zn ions (Zn1 and Zn2) and interacts with both zincs. The a-helix interacts only with Zn1 and extends towards the carboxy terminus of the activation domain. Zn1 is coordinated by Cys 22, His 33, Cys 34 and Cys 37 of Tat ( Fig. 2d, e ), and Zn2, located 10.7 Å away, is coordinated by Cys 25, Cys 27 and Cys 30 of Tat and Cys 261 of cyclin T1 ( Fig. 2f, g) . The observed coordination of Zn ions explains earlier mutational studies pointing to the importance of His 33 and all cysteines, except Cys 31, in the Zn-dependent function of Tat 23, 24 . The Cys 31 is replaced by a serine in several Tat variants and this replacement does not diminish the protein function 25 . The zinc fingers (ZnFs) in Tat should be considered unique because protein fold searches did not uncover similar ZnF motifs in any other protein.
In addition to the main-chain hydrogen bonds involved in secondary structure elements, only six intramolecular hydrogen bonds were found in Tat ( Supplementary Fig. 2 ). Three of these hydrogen bonds were between the side chain of Lys 41 and main-chain oxygens of Thr 23, Cys 25 and Cys 30. The latter intramolecular interactions seem to be crucial for the structural integrity of the cysteine-rich/core module because mutation of Lys 41 impairs the activity of Tat 25, 26 .
Recently the crystal structure of the fusion of equine cyclin T1 and equine infectious anaemia virus (EIAV) Tat in complex with EIAV TAR RNA was reported 27 . The basic RNA-recognition motif of EIAV Tat adopts a helical structure whose flanking regions interact with an equine cyclin T1 and both proteins coordinate the stem-loop structure of EIAV TAR 27 . However, the key residues in EIAV TAT and equine cyclin T1 involved in ternary complex formation with TAR RNA, are different in HIV-1 Tat and human cyclin T1 (refs 27-29) . The TAR RNAs from HIV-1 and EIAV have different structures as well 27, 30 . Moreover, the photocross-linking and protein footprinting studies 31 show that HIV-1 TAR RNA loop interacts with cyclin T1 residues 252-260, which is far from the EIAV TAR RNA docking site. These differences make it difficult to model HIV-1 TAR binding to the TatNP-TEFb complex on the basis of the structure of the EIAV complex 27 . However, it is appropriate to apply the structure of HIV-1 TatNP-TEFb to model the portion of the activation domain for the EIAV Tat sharing high sequence identity with HIV-1 Tat in ZnF and core regions ( Supplementary Fig. 3a ). The proposed model of EIAV Tat ZnF and core regions in complex with cyclin T1 is shown in Supplementary Fig. 3b and displays an uninterrupted connection with the basic region. The high sequence conservation of the central ZnF-core motif in Tat proteins, compared with poorly conserved flanking regions, indicates that the binding of ZnF-core motif to a cyclin T1 surface is the most conserved structural feature shared among Tat transcriptional regulators.
TatNP-TEFb interactions
Interactions between Tat and P-TEFb can be divided into four areas (Fig. 3 ). The first area involves a U-shaped, acidic/proline-rich region of Tat and a wide depression between the two cyclin repeats of cyclin T1. The second area involves a b-turn in the acidic/proline-rich region of Tat and the T-loop of Cdk9. In the third area, the cysteine-rich region and a core region of Tat interact with a depression between the cyclin repeats of cyclin T1 and a point close to the helix H59. The fourth area involves the second ZnF of Tat and the Cys 261 of cyclin T1.
Tat possesses an extended hydrophobic patch comprised of the amino-terminal methionine and amino acid residues from a cysteinerich region and the core region that are packed against the hydrophobic surface of cyclin T1 ( Supplementary Fig. 4a ). Moreover, several intermolecular van der Waals contacts can be seen at discrete locations ( Supplementary Fig. 4b , c).
Tat forms numerous direct and water-mediated hydrogen bonds with both Cdk9 and cyclin T1 (Supplementary Table 1 and Supplementary Figs 5 and 6). The fewer Tat-stabilizing intramolecular hydrogen bonds compared with intermolecular TatNP-TEFb hydrogen bonds indicate that overall the conformation of Tat is determined predominantly by its interactions with P-TEFb.
Conformational changes of Tat and P-TEFb
Several solution structures of Tat variants have been reported 32 . In the absence of interacting partners, Tat does not have prominent secondary structure elements, indicating the flexible nature of free Tat proteins 32 . However, upon interaction with P-TEFb and two Zn ions, the activation domain of Tat acquires a well ordered structure ( Fig. 1) .
To elucidate Tat-induced conformational changes in P-TEFb, we compared the structure of the TatNP-TEFbNATP complex with the structure of P-TEFbNATP (PDB ID 3blq) solved previously 21 . Although there are differences in P-TEFb subunit constructs and crystal packing, four notable changes were observed. First, Tat binding resulted in the unfolding and disordering of the cyclin T1 a-helix HC (residues 253-256) and a 4.6 Å displacement of the C-terminal portion of the preceding a-helix H59 (Fig. 4a) . These changes expose a buried surface in cyclin T1 that is used for the binding of the ZnF and core region sequences of Tat. Second, when the cyclin T1 subunits of P-TEFbNATP and TatNP-TEFbNATP were aligned, a significant, 8.5u rotation was detected for the Cdk9 subunit ( Fig. 4b) . Third, the shift of phospho-Thr 186 by 2.6 Å resulted in the formation of two hydrogen bonds with Arg 65 and one additional hydrogen bond with Arg 148 (Fig. 4c ). Fourth, the concerted allosteric changes result in the switch of the conformations in the b 1 b 2 -loop and b 3 aC-loop that are in close proximity to the ATP binding site ( Fig. 4d) . To understand the possible sequence of events leading to the latter conformational changes upon Tat binding, we superimposed the Cdk9 subunit of TatNP-TEFbNATP with the Cdk9 subunit of P-TEFbNATP. Figure 4d demonstrates a significant shift of the first cyclin repeat of cyclin T1 towards Cdk9 in the structure of TatNP-TEFbNATP relative to structure of P-TEFbNATP. This shift reaches up to 4.8 Å and leads to steric hindrance between the a-helix H5 of cyclin T1 and the b 3 aCloop of Cdk9, in particular between Val 134 and Ser 138 of cyclin T1 and Gly 58 and Met 52 of Cdk9, respectively (Fig. 4e ). To release this steric hindrance, the Gly 58 of Cdk9 is shifted 2.4 Å away from Val 134 of cyclin T1 and the part of the Cdk9 b 3 aC-loop comprised of residues 51-55 changed their conformation. As result of this conformational change the Leu 51 clashes with Phe 30, pushing it away and forcing the residues 25-32 of b 1 b 2 -loop to acquire a conformation that is different than that in P-TEFbNATP (Fig. 4e ). The Tatinduced conformational changes in Cdk9 modify the substrate-binding surface of P-TEFbNATP. This provides a structure-based explanation for the earlier findings showing that Tat-bound P-TEFb phosphorylates not only the Ser 2 but also the Ser 5 in the heptad repeats of the RNA polymerase II large subunit C-terminal domain 17 .
Structural constraints for Tat mutations HIV-1 genes are prone to rapid mutation leading to high genetic variability. HIV-1 has been classified into three genetic groups: major (M), outlier (O) and new (N) that are non-M and non-O 33 . Most HIV-1 infections are caused by group M viruses. The group M is divided into nine subtypes: A-D, F-H, J and K 33 . Genetic variation within a subtype is 15-20%, and is 25-35% between subtypes 33 . In ARTICLES line with this observation, Tat tolerates up to 40% sequence variation without loss of transcriptional activity 32 . Our structure provides insight into how mutations in Tat are tolerated. To facilitate the description of sequence variations, we produced sequence logos 34 of the Tat activation domain using the alignment of 1,118 Tat sequences 35 (Fig. 5a ). The alignment indicates that half of the residues have a higher degree of conservation, with 14 invariant residues and 10 residues with randomly occurring polymorphs (Fig. 5b) . The apparent reasons for the conservation are the following: involvement in Zn coordination, interaction with the T-loop of Cdk9, stabilization of Tat structure by intramolecular hydrogen bonds, interaction with a hydrophobic surface of cyclin T1, formation of hydrogen bonds with cyclin T1, and providing rigidity to the loop connecting the acidic/proline-rich region and a cysteine-rich region. There is no alternative for glycine at position 15, because any mutation would create a backlash with Asn 53 side chain of cyclin T1 and disrupt its hydrogen bond with Gln 17 of Tat ( Supplementary Fig. 7) . The analysis of TatNP-TEFb structure alone does not provide an immediate explanation for the functional importance of Lys 28. However, it explains an earlier finding indicating that acetylated Lys 28 interacts with Asn 257 of cyclin T1 and facilitates the formation of TatNTARNP-TEFb complex 36 . Indeed, Lys 28 is located at the surface of the second ZnF (Fig. 2f ); in close proximity to the missing cyclin T1 residues (252-260) linking Cys 261 to the cyclin domain and harbouring Asn 257. Acetylated Lys 28 could reach the Asn 257 side chain and form an intermolecular hydrogen bond.
Residues with a high mutation rate are divided into two groups: those with predominantly functionally equivalent substitutions ( Fig. 5c ) and those with a variety of substitutions (Fig. 5d ). All these residues, except Gln 35 and Ile 39, are fully or partially exposed. None of the observed mutations would disrupt interactions of Tat with P-TEFb. Gln 35 penetrates deeply into a depression on cyclin T1 and forms a hydrogen bond with Asn180 ( Supplementary Fig. 7a ). All Gln 35 mutations (Fig. 5a ), except tyrosine, could be accommodated with minor adjustments in the positions of surrounding side chains. However, modelling of tyrosine shows that it may shift the N-terminal methionine without disrupting the TatNP-TEFb (Supplementary Fig. 7a ). Another frequently mutated residue buried at the TatNP-TEFb interface is Ile 39 (Fig. 5a ). The Ile 39 side chain faces a groove that is occupied by a water molecule ( Supplementary  Fig. 7c ), and hence all Ile 39 mutations could be easily accommodated without disrupting the TatNP-TEFb.
Implications for P-TEFb activation
The TatNP-TEFb structure provides insight into how Tat functions in recruiting P-TEFb to the HIV LTR. The first step of this process involves a Tat-induced release of P-TEFb from the 7SK snRNPcontaining complex 13, 37 . Most of P-TEFb within the cell is held in an inactive form by HEXIM1, which is bound to 7SK snRNA along with other proteins 38, 39 . Several experiments show that inhibition of P-TEFb by HEXIM1 resembles the inhibition of Cdk2NcyclinA by p27 kip1 (ref. 40 ). In the Cdk2NcyclinANp27 kip1 crystal structure the side chains of Phe 87 and Tyr 88 of p27 kip1 enter the active site cleft and prevent the binding of ATP 40 . Mutational studies of invariant tyrosine and phenylalanine residues of HEXIM1 showed that Tyr 271 and Phe 208 mutations relieved the inhibitory activity of P-TEFb without dissociation of HEXIM1 (ref. 41 ). These results indicate that HEXIM1 blocks the binding of ATP to Cdk9 in a manner similar to p27 kip1 . In such a case the flipping of the b 1 b 2 -loop conformation would lead to dissociation from P-TEFb ( Supplementary Fig. 8 ). In support of this idea, P-TEFb with a shorter cyclin T1 (1-254) and a missing a-helix HC was not capable of binding 7SK snRNA 42 , indicating the important contribution of this helix to P-TEFbNHEXIM1N7SK snRNA complex formation. Because Tat unfolds the HC of cyclin T1 this also may facilitate the release of HEXIM1 ( Supplementary Fig. 8 ).
Conclusions
The emergence of multidrug resistant HIV-1 strains requires the development of new drugs capable of stopping viral replication 43 . Tat has a major role in the viral replication and remains a viable target for crystallographic studies and structure-based drug design. The structure of TatNP-TEFb described here revealed a large interaction interface buried between these two factors and showed how local conformational changes caused by Tat mutations could be tolerated without disruption of the complex. The extended and flexible interaction-dependent conformation of Tat suggests that designing compounds that would block the interaction of Tat with P-TEFb would be a challenging task. The disadvantage of such inhibitors might be also the interference with the function of cellular factors (for example HEXIM1, BRD4, etc.) that bind to and are essential for the regulation of P-TEFb. On the other hand, the Tat binding changes the overall shape and surface of P-TEFb. This provides an opportunity for the design of inhibitors that would not bind to or inhibit the normal cellular function of P-TEFb, but would be specific only to the form of P-TEFb used by the virus. 
METHODS SUMMARY
C-terminally His-tagged human Cdk9 (1-345), human cyclin T1 (1-266) and HIV-1 Tat (1-86) were co-expressed in insect cells and purified by Ni-NTA and Mono S columns. The purified TatNP-TEFb complex was crystallized using the sitting-drop vapour-diffusion method. The TatNP-TEFbNATP crystals were obtained by soaking AMP-PNP and magnesium chloride into the TatNP-TEFb crystals. Transformation of crystals to a low-humidity form markedly improved the diffraction enabling the complete data collection at high resolution using synchrotron radiation. The TatNP-TEFb structure was solved using molecular replacement method and refined at 2.1 Å resolution. The positions of AMP-PNP and magnesium in TatNP-TEFbNATP structure were determined by the difference Fourier map and the structure was refined at 3 Å resolution. Both structures exhibited electron density maps of high quality and provided the models with excellent geometry.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
METHODS
Expression of TatNP-TEFb complex. Sf9 insect cells were co-infected with three baculoviruses that individually directed the expression of C-terminally His-tagged human Cdk9 (1-345), human cyclin T1 (1-266) and HIV-1 Tat (1-86). The three coding sequences were individually cloned into the pENTR/ SD/D-TOPO vector (Invitrogen) after PCR amplification. The baculoviruses were generated using BaculoDirect C-Term Expression kit (Invitrogen), and these viruses were transfected into Sf9 cells following the manufacturer's instructions. The viruses were amplified several times to obtain viral stocks with 10 8 plaque-forming units per millilitre. Stocks were titred by infecting individual wells of a six-well plate containing 1 3 10 6 Sf9 cells with 0.001, 0.01, 0.1, 1, 10 or 100 ml of the stocks. After 48 h the cells were fixed with 3.7% formaldehyde for 15 min and stained using first a gp64 antibody (Novagen), then by an alkaline phosphatase-coupled goat anti-mouse IgG (Sigma-Aldrich); colour development with 5-bromo-4-chloro-39-indolyphosphate p-toluidine Salt (BCIP) and Nitro-Blue tetrazolium chloride (NBT) (Sigma-Aldrich) followed. The presence of the gene of interest was determined by conducting PCR on DNA isolated by phenol extraction from the stocks.
Large scale production of the TatNP-TEFb complex was carried out using baffled 2 l glass Erlenmeyer flasks containing 1 l Sf-900 serum-free medium (GIBCO) with 1.5 3 10 6 Sf9 cells/ml. The flasks were incubated at 70 r.p.m. in a rotary shaker at 27uC. Typically, 6 l of cells were infected at once by adding 20 ml of each of the three viral stocks to each litre of culture. The flasks were then incubated for an additional 72 h. Purification of the TatNP-TEFb complex. To avoid protein degradation, all solutions and equipment were kept cold and the purification was performed swiftly. Cells were collected from six 1 l cultures by spinning for 10 min at 4,200 r.p.m. in a Beckman JS-4.2 rotor (3,600g). Each of the six pellets was resuspended in 20 ml of PBS supplemented with 1 mg ml 21 E-64 protease inhibitor (Calbiochem), 13 Roche Complete Protease Inhibitor (Roche), and 0.1% of a saturated phenylmethylsulphonyl fluoride (PMSF) solution in isopropanol then transferred to 40 ml tubes. After centrifuging at 3,000 r.p.m. for 5 min in a Beckman JS 13.1 rotor (1,000g), the supernatants were decanted and pellets were resuspended in 12 ml of lysis buffer (5 mM imidazole, 150 mM NaCl, 10 mM Tris pH 7.8, 1% Triton, 2 mM MgCl 2 , 1 mg ml 21 E-64, 13 Roche Complete Protease Inhibitor, and 0.1% PMSF solution). Lysates were combined into three 50 ml plastic beakers on ice, and each was sonicated five times for 15 s with a 5-min pause between bursts. Cell lysates were combined and brought to 500 mM NaCl by adding 5 M NaCl and mixing vigorously then centrifuged at 45,000 r.p.m. for 45 min in a Beckman 55.2Ti rotor (167,000g) in Oak Ridge tubes. The high-speed supernatant was incubated with 4.5 ml of Qiagen Ni-NTA agarose that had been equilibrated in lysis buffer containing 500 mM NaCl. After 60 min the resin was pelleted at 1,200 r.p.m. for 3 min in a Beckman JS-13.1 rotor (146g). The resin was resuspended in wash buffer (5 mM imidazole, 500 mM NaCl, 10 mM Tris pH 7.8, 1% Triton, and 0.1% PMSF solution) and transferred equally into three 20 ml Bio-Rad disposable columns. Each column was washed successively with 10 ml of wash buffer, 15 ml of HSW (25 mM imidazole, 1 M NaCl, 10 mM Tris pH 7.8, 1% Triton, and 0.1% PMSF solution), and 15 ml of 70 mM HGKE wash (25 mM imidazole, 70 mM KCl, 25 mM HEPES pH 7.6, 15% glycerol, 0.1 mM EDTA, 1% Triton, and 0.1% PMSF solution). Each column was then eluted with 6 ml of HGKE wash supplemented with 300 mM imidazole. The eluted material was pooled and centrifuged at 12,500 r.p.m. for 15 min in a Beckman JS-13.1 rotor (16,000g) and then loaded onto a 1 ml Mono S column that had been equilibrated in 70 mM HK buffer (70 mM KCl, 10 mM HEPES pH 7.6, 1 mM dithiothreitol (DTT), and 0.1% PMSF solution). After a 5 ml wash the column was eluted with a 17.5 ml gradient from 70 to 620 mM KCl in HK buffer ( Supplementary Fig. 9a ). Free P-TEFb eluted at 220 mM KCl and the TatNP-TEFb complex at 420 mM KCl. The peak fractions were relatively free of contaminating proteins ( Supplementary Fig. 9b ). The purification protocol was performed more than 20 times with minor modifications and usually resulted in 5-10 mg of the TatNP-TEFb complex per 6 l of cells. The samples obtained were kept in small aliquots at 280 uC. Crystallization. The frozen TatNP-TEFb samples were thawed on ice, dialysed against 400 mM KCl, 10 mM HEPES buffer (pH 7.5), and 2 mM tris(2carboxyethyl)phosphine hydrochloride (TCEP), then concentrated to 5-6 mg ml 21 using Millipore Ultrafree centrifugal devices. Only few fractions reached these concentrations because sudden precipitation occurred on most fractions even at lower concentrations. The state of sample aggregation was monitored by dynamic light scattering. Application of the solubility screening protocol described previously 44 did not improve the sample solubility and aggregation. Initial crystallization screening was performed at a temperature of 295 K in 96-well plates using 50% diluted Crystal Screen and Crystal Screen 2 solutions (Hampton Research) by the sitting-drop vapour-diffusion method by mixing 1 ml of complex solution with 1 ml of reservoir solution. TCEP (1 mM) was added to each condition and finally 400 mM KCl was added to each reservoir. Crystals appeared in 37th condition of the Crystal Screen 2 containing 50 mM HEPES buffer (pH 7.5), 5% PEG 8,000, 2 mM TCEP, and 2% ethylene glycol in the crystallization drop plus 400 mM KCl in the reservoir only. Variations in concentration of the components, molecular mass of PEGs, buffers and pH, and inclusion of additives from Hampton Research Additive Screen revealed the following conditions producing crystals of better shape: 50 mM HEPES buffer (pH 7.5), 4.25-5% PEG 20,000, 1 mM TCEP, and 20 mM glycylglycyl-glycine mixed with protein solution. The reservoir solution contained also 400 mM KCl. Most drops produced small needle-like crystals in 1-2 days; however, in some of remaining clear drops larger crystals of hexagonal prism shape ( Supplementary Fig. 10a ) appeared in 1-3 weeks and sometimes after 1-3 months. The growth of crystals normally continued for 2-4 weeks, reaching the maximum dimensions of 0.25 3 0.25 3 1.5 mm 3 . The polarization of light by these crystals was barely detectable. The SDS-PAGE of dissolved crystals showed all three subunits of TatNP-TEFb in stoichiometric (1:1:1) proportions ( Supplementary Fig. 10b ). The TatNP-TEFbNATP crystals were obtained by soaking the TatNP-TEFb crystals in crystallization solution with 1 mM ATP analogue AMP-PNP and 5 mM magnesium chloride for 40 min. X-ray diffraction data collection and processing. For the preliminary studies the crystals were soaked in cryoprotectant for a few seconds, scooped with a nylon-fibre loop and flash-cooled in a dry nitrogen stream at 100 K. The best cryoprotectant was obtained by adding 25% (v/v) glycerol or ethylene glycol to the reservoir solution. Preliminary diffraction data were collected at cryogenic temperature on a Rigaku R-AXIS IV imaging plate using Osmic VariMax HR mirror-focused CuK a radiation from a Rigaku FR-E rotating anode operated at 45 kV and 45 mA. Despite a large volume of crystals, the diffraction was poor for most crystals, reaching a resolution of only 4.2-4.5 Å . Occasionally some crystals diffracted better, up to a resolution of 3.5-3.8 Å . Inspection of unit cell parameters showed that, in general, better-diffracting crystals had slightly shorter (1-1.5 Å ) parameters a and b. Because the crystals with such properties are often capable of transformation to a low-humidity form, we started such experiments with TatNP-TEFb crystals with modification of earlier described experimental setup 45 . Instead of mounting the crystal directly in capillary, we mounted the cryoprotectant-soaked crystal (with the content of glycerol or ethylene glycol reduced to 12-16% v/v) in a MiTeGen MicroMeshes, wiped the excess but not all solution around the crystal with the fine-cut filter paper over the top of the well with cryoprotectant solution, immediately placed it in a capillary having a cryoprotectant solution on the wider end and sealed its bottom touching the goniometer base (without using the hot wax). Cryoprotectant in capillary was replaced with solutions each having the PEG 20,000 concentration increased by 3% every 5-10 min until initial signs of transformation such as the reduction of the volume of the remaining solution around the crystal. Then the capillary was removed and the crystal was flash-cooled under the stream of nitrogen gas. It was important not to reach the point of transformation when an apparent 'sweating' of crystal occurs because further reduction of the relative humidity results in marked shrinkage of crystals, especially along the axis c, and complete loss of diffraction. This method of transformation to a low-humidity form was effective only for crystals having cross section of over 0.15 mm, probably due to fast dehydration of smaller crystals. The most successful transformation of TatNP-TEFb crystals was accompanied with the reduction of unit cell parameters a and c by 4.5 Å and 1.5 Å , respectively, and extension of the X-ray diffraction resolution limits from 4.5-3.5 Å to 2.1 Å . The high-resolution diffraction data were collected using synchrotron radiation at the Advanced Photon Source on the Northeastern Collaborative Access Team beamlines BL24ID-C and BL24ID-E. To minimize the radiation damage, complete data sets were obtained from one crystal of TatNP-TEFb and one crystal of TatNP-TEFbNATP, each exposed at six positions. The data set for the calculation of the Zn anomalous diffraction signal was collected by exposing only one position of the crystal with a beam intensity reduced to 20%. The intensity data were indexed, integrated, and scaled using the HKL2000 program package 46 (Supplementary Table 2 ). Structure determination and refinement. The structure was determined by the molecular replacement method starting with the coordinates of P-TEFb (PDB entry 3blh) 21 . All amino acid residues with temperature factors above 80 Å 2 were excluded from the positioned model before the calculation of phases. Density modification with CNS software 47 reduced the model bias and improved the electron density maps. The building of the Tat structure and missing parts of the Cdk9 and cyclin T1 subunits, as well as adjustment of the initial model, was performed manually in five rounds with TURBO-FRODO software. The positions of Zn atoms were confirmed using anomalous difference Fourier map. The refinement of the completed TatNP-TEFb structure was performed using conjugate gradient minimization, simulated annealing, and temperature factor refinement CNS protocols 47 . Finally, 341 water molecules were added with the
